A long-time darling of venture capital, the gastrointestinal sector has yet to meet expectation of VCs who wagered on technologies to treat gastroesophageal reflux disease, Barrett’s esophagus and even obesity. But some notable acquisitions, including Covidien’s purchase of privately held Barrx, may present a ray of hope for investors in GI companies.
More:
Buyer Appetite Might Appeal To GI Device Investors
Tags: barrx, esophagus-and, gastrointestinal, may-present, meet-expectation, sector-has, some-notable, venture-capital